Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Mar;148(3):317-22.
doi: 10.1001/archdermatol.2011.342. Epub 2011 Nov 21.

Impact of smoking in cutaneous lupus erythematosus

Evan W Piette  1 , Kristen P Foering, Aileen Y Chang, Joyce Okawa, Thomas R Ten Have, Rui Feng, Victoria P Werth
Affiliations
Comparative Study

Impact of smoking in cutaneous lupus erythematosus

Evan W Piette et al. Arch Dermatol. 2012 Mar.

Erratum in

  • Arch Dermatol. 2012 Dec;148(12):1369

Abstract

Objective: To investigate cigarette smoking in cutaneous lupus erythematosus (CLE).

Design: Prospective longitudinal cohort study.

Setting: Urban cutaneous autoimmune disease clinic.

Participants: A total of 218 individuals with CLE or systemic lupus erythematosus and lupus nonspecific skin disease seen between January 5, 2007, and July 30, 2010.

Main outcome measures: Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores to assess disease severity and response to treatment and Skindex 29+3 scores to assess patient quality of life.

Results: Current smokers with lupus erythematosus had higher median CLASI scores (9.5) than did never (7.0) and past (6.0) smokers with CLE (P = .02). Current smokers had higher median scores on all the Skindex 29+3 subsets. Current smokers taking hydroxychloroquine sulfate had higher quinacrine hydrochloride use than did nonsmokers (P = .04). Two to 7 months after enrollment, current smokers (median CLASI change, -3) treated with only antimalarial agents improved more than never (1) and past (0) smokers (P = .02). Eight months or more after enrollment, current smokers (CLASI change, 3.5) treated with antimalarial drugs plus at least 1 additional immunomodulator improved less than never (-1.5) and past (0) smokers (P = .04).

Conclusions: Current smokers with lupus erythematosus had worse disease, had worse quality of life, and were more often treated with a combination of hydroxychloroquine and quinacrine than were nonsmokers. Never and past smokers showed greater improvement when treated with antimalarial agents plus at least 1 additional immunomodulator. Current smokers had greater improvement when treated with antimalarial drugs only.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differences in smoking status between lupus subjects with SLE + skin relative to subjects with CLE-only (p = 0.006).
Figure 2
Figure 2
Median CLASI scores for subjects in the lupus database at enrollment. Both never and past smokers differed significantly from current (p = 0.017, post-hoc Dunn’s test indicated *p < 0.05 for both never versus current and past versus current; bars represent interquartile range).
Figure 3
Figure 3
Median Skindex 29-3 scores compared by smoking status. Note that current smokers had higher scores in all subjects (*p < 0.05; **p < 0.01; bars represent interquartile range).
See this image and copyright information in PMC

References

    1. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–381. - PubMed
    1. Boeckler P, Cosnes A, Frances C, Hedelin G, Lipsker D. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol. 2009 Sep;145(9):1012–1016. - PubMed
    1. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009 Mar;145(3):244–248. - PubMed
    1. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889–894. - PMC - PubMed
    1. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009 Mar;145(3):255–260. - PMC - PubMed

Publication types

MeSH terms